Opneja A, Cioffi G, Alahmadi A, et al. - Prior to- as well as post- sorafenib approval by FDA (in 2007), the pattern of use of single agent anticancer therapy (SAACT) in the treatment as well as survival of advanced hepatocellular carcinoma (aHCC) was investigated. Using the National Cancer Database, adult patients suffering from HCC and managed with only ACT (anticancer therapies) from 2004 – 2014 were selected. During three time periods, patients were evaluated: 2004–2006 (pre-sorafenib (PS)), 2007–2010 (early sorafenib (ES)) and 2011–2014 (late sorafenib (LS)). Over time, the rate of adoption of SAACT increased significantly: 6.2% PS, 15.2% ES, and 22.2% LS. Findings showed an overall improvement in survival among aHCC patients managed only with ACT. However, there remained significant differences between facility type, insurance status, and income.